Atika Capital Management’s Coherus Oncology CHRS Stock Holding History

Atika Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-195,000	Closed	-$3.16M	–	98
2020 Q1	$3.16M	Hold	195,000	–	–	0.61%	51
2019 Q4	$3.51M	Buy	195,000 +9,500	+5%	+$175K	0.68%	56
2019 Q3	$3.76M	Sell	185,500 -24,500	-12%	-$490K	0.79%	48
2019 Q2	$4.64M	Buy	210,000 +22,000	+12%	+$382K	0.91%	49
2019 Q1	$2.56M	Buy	+188,000	New	+$2.51M	0.52%	62

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Atika Capital Management's CHRS Position: Q2 2020 in Review

Atika Capital Management sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 195,000 shares — an estimated $3.16M sold.

Atika Capital Management first reported a position in CHRS in Q1 2019 and held it in 5 quarters. The position peaked at $4.64M in Q2 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

Atika Capital Management reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
Atika Capital Management sold 195,000 Coherus Oncology shares in Q2 2020, an estimated $3.16M.
Atika Capital Management first reported a position in Coherus Oncology in Q1 2019 and held it in 5 quarters.
Atika Capital Management's Coherus Oncology position peaked at $4.64M in Q2 2019.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Atika Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.